Questions? Call 800-624-6242
|
|
|
|
|
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Page xvii
List of Tables and Figures
TABLES
| 2.2
|
Initial Signs and Symptoms of MS,
|
32 |
| 2.3
|
Prognostic Relapse Indicators,
|
34 |
| 2.4
|
Information Provided by Neuroimaging,
|
38 |
| 2.5
|
Proposed CSF Disease Markers in MS,
|
44 |
| 2.6
|
Poser Diagnostic Criteria for MS,
|
46 |
| 2.7
|
MRI Criteria for Definite MS,
|
46 |
| 2.8
|
Evoked Potentials as a Diagnostic Tool in MS,
|
47 |
| 2.9
|
Disease-Modifying Therapies for Relapsing MS,
|
49 |
| 2.10
|
Clinical Pathological Correlations in Common Syndromes of MS,
|
62 |
| 2.11
|
Selected Diseases That Are Believed to Be Autoimmune Based,
|
69 |
| 2.12
|
Possible Autoantigens in MS,
|
71 |
| 2.13
|
CNS Demyelinating Diseases That Resemble MS,
|
85 |
| 2.14
|
Koch's Postulate on Causations of Disease by a Pathogen,
|
88 |
| 2.15
|
Agents Isolated or Implicated in the Etiology of MS,
|
89 |
| 2.16
|
Animal Models of MS,
|
91 |
| 2.17
|
Comparison Between Multiple Sclerosis and EAE,
|
92 |
| 2.18
|
Animal Viruses That Induce Demyelination,
|
96 |
| 3.1
|
Medications Used to Treat Depression,
|
124 |
| 3.2
|
Depression and Beta-Interferon,
|
126 |
| 3.3
|
Medications Used to Treat Spasticity,
|
134 |
| 3.4
|
Indications of Bladder Dysfunction,
|
141 |
|
|
|
|
|
|
